4-[(3R)-2,3-dihydro-1H-pyrrolizin-3-yl]-3-fluorobenzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯嗪
• 英文名称: 4-[(3R)-2,3-dihydro-1H-pyrrolizin-3-yl]-3-fluorobenzonitrile
• 化学式: C₁₄H₁₁FN₂
• 分子量: 226.25
• InChiKey: SQMSVEPJMBDEEB-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  28.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Use of an Adrenal Hormone-Modifying Agent
  申请人：Hu Qi-Ying

  公开号：US20140171392A1

  公开（公告）日：2014-06-19

  The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(R a )(R b ) wherein R a and R b are independently —(C 1 -C 4 ) alkyl, or —(C 1 -C 4 ) alkyl-(C 5 -C 7 ) aryl, wherein each of R a and R b is optionally substituted by —(C 1 -C 4 ) alkoxy; R 1 , R 2 , and R 3 , are independently hydrogen, halogen, cyano or —(C 6 -C 10 ) aryl, wherein said —(C 6 -C 10 ) aryl is optionally substituted by halogen, with the proviso that no more than one of R 1 , R 2 , and R 3 is hydrogen; and R 4 and R 5 are hydrogen; or a pharmaceutically acceptable salt thereof.
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF SUBSTANCE USE DISORDERS, ADDICTION, AND PSYCHIATRIC DISORDERS
  申请人：EMBERA NEUROTHERAPEUTICS, INC.

  公开号：US20180185375A1

  公开（公告）日：2018-07-05

  The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the HPA axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, codeine, hydrocodone, nicotine, alcohol, prescription medication (e.g., Percodan®, Percoset®), marijuana, tobacco, methadone, food), addiction to an activity (e.g., gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, ADHD, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (e.g., Prader Willi Syndrome), obesity, depression, menopause, premenstrual syndrome (PMS), obsessive compulsive disorder (OCD), social anxiety, generalized anxiety disorder, dysthymia, or schizophrenia.